First NMR Analyser Designed Specifically for the Clinical Laboratory 

Agilent Technologies Inc have announced that it has entered into an exclusive supply agreement with LipoScience Inc to provide nuclear magnetic resonance (NMR) components for LipoScience’s Vantera Clinical Analyser. The analyser is the first fully-automated NMR diagnostic platform designed specifically for the clinical laboratory and cleared by the US Food and Drug Administration.

The Vantera Clinical Analyser, which recently received 510(k) clearance from the FDA, combines proprietary signal-processing algorithms and NMR spectroscopic detection to identify and quantify concentrations of lipoproteins and, potentially, small-molecule metabolites.

“We are extraordinarily pleased to join forces with LipoScience to provide key components for this leading-edge diagnostic platform,” said Nick Roelofs, President of Agilent’s Life Sciences Group.

“LipoScience is pioneering a new field of personalised diagnostics based on NMR technology. Broadening access to our proprietary diagnostic tests is central to our vision of becoming a clinical standard of care. We value Agilent’s NMR expertise and look forward to partnering with them in our efforts to decentralise our NMR clinical analyser to leading clinical laboratories and academic centres of excellence,” added Richard O. Brajer, CEO of LipoScience.